K_DDiscovery LLC

Design and de-risk of early discovery platforms and assets

Target validation and translational alignment from day one

Compound profiling and candidate selection with clinical focus

IP strategy aligned to long-term asset value

Independent technical validation of assets and platforms

Risk and timeline analysis across discovery and preclinical stages

Chemistry team, CRO, and infrastructure assessment

Expert witness support for IP, scientific claims, or diligence matters

Execution of hit-to-lead and lead optimization workflows

Integration of drug-like property and developability criteria

Vendor management across CROs and alliance partners

CMC and clinical transition planning with investor-aligned milestones

20+ years of experience with VCs, pharma partners and CRO networks

Over $150M raised across Series B/C and strategic alliances

Proven record: 10+ clinical candidates and approval of Tazverik®

Broad experience scaling discovery organizations and platforms